ClinicalTrials.gg
CompletedNCT03444480Updated Feb 23, 2018

A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers

A Phase 1 interventional study of Remimazolam Tosylate in Anesthesia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-23.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2014, registered Aug 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the Pharmacokinetics/Pharmacodynamics and safety of Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.

Read the detailed description
  1. Study the Pharmacokinetics/Pharmacodynamics of Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.
  2. Study the reversal effect and time required of Flumazepine on Rimazolam'effect.
  3. Study the Safety of Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.
02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 and ≤55 years.
  • Weight range 50 to 100 kg and (BMI) 18 to 26 kg/m2.
  • Willing and able to comply with the requirements of the protocol.
  • Provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Abnormal results of physical or laboratory examination with clinical significance
  • With a history of laboratory results that show the presence of surface antigen (HBs Ag), antibody (HCV Ab), or (HIV).
  • With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor.
  • Subject with abnormalities in baseline 12-lead (ECG) or vital signs(SBP \<90 mmHg or >140 mmHg,DBP \<50 mmHg or >90 mmHg;Hr \<50 bpm or >100 bpm;SpO2 \<95%).
  • Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are .
  • Receipt of other medication within 14 days of the first study day.
  • Blood donation greater than 200 ml or participation in a clinical study of an unlicensed drug in the previous 3 months.
  • History of smoking or alcohol abuse within 6 months of screening.
  • History of grapefruit juice or any other foods affect the activity of cytochrome P450 3A4() within 7 days of screening.
  • Pregnant,lactating.
  • Mallampati score ≥3.
  • Patients who in the opinion of the investigator may not be able to comply with the requirements of the study are not eligible
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosylate 1

    IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start, 0.5 mg Flumazenil is administered

    Drug: Remimazolam Tosylate

  • Experimental
    Remimazolam Tosylate 2

    IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered

    Drug: Remimazolam Tosylate

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of Remimazolam in human plasma.

    Time frame: From prior to study drug injection until 4 hours post-dose

  2. Area under the plasma concentration versus time curve (AUC) of Remimazolam in human plasma.

    Time frame: From prior to study drug injection until 4 hours post-dose

  3. Peak Plasma Concentration (Cmax) of M01 in human plasma.

    M01 is the main metabolite of Remimazolam

    Time frame: From prior to study drug injection until 4 hours post-dose

  4. Area under the plasma concentration versus time curve (AUC) of M01 in human plasma.

    M01 is the main metabolite of Remimazolam

    Time frame: From prior to study drug injection until 4 hours post-dose

Secondary outcomes

  1. Safety by measurement of Adverse Events.

    Time frame: From start of study drug injection to patient discharge (approx. 2 days)

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
08

References and documents

Publications

  • Chen X, Sang N, Song K, Zhong W, Wang H, Jiang J, Huang Y, Hu P. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. Clin Ther. 2020 Apr;42(4):614-624. doi: 10.1016/j.clinthera.2020.02.006. Epub 2020 Mar 13. PubMed 32178858 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Aug 2014, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2015
First posted
Feb 23, 2018
StartActual
Jul 23, 2014
Primary completionActual
Aug 16, 2014
CompletionActual
Aug 16, 2014
Last update
Feb 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444480
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Jul 23, 2014
Primary completion
Aug 16, 2014
Completion
Aug 16, 2014
Last update
Feb 23, 2018

Study contacts

Pei Hu
principal investigator · Peking Union Medical College

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion